Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Yangxinshi Tablet in Improving Exercise Tolerance in Patients With Chronic Coronary Syndrome(Qi Deficiency and Blood Stasis Syndrome):A Randomized, Double-blind,Placebo-parallel-controlled,Multicenter Clinical Study

NCT05978089 is registered in ClinicalTrials.gov with Dongzhimen Hospital, Beijing as lead sponsor.

NCT NCT05978089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05978089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Yangxinshi Tablet in Improving Exercise Tolerance in Patients With Chronic Coronary Syndrome(Qi Deficiency and Blood Stasis Syndrome):A Randomized, Double-blind,Placebo-parallel-controlled,Multicenter Clinical Study
Lead sponsor
Dongzhimen Hospital, Beijing
Phase
Phase 4
Overall status
Unknown status
Start date
November 8, 2023
Completion date
December 31, 2025
Enrollment
120 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic coronary syndrome